Vulvovaginal Candidiasis - Pipeline Review Key Trends, Size, Growth, Shares And Forecast Research Report 2016

Researchmoz added Most up-to-date research on "Vulvovaginal Candidiasis - Pipeline Review, H1 2016" to its huge collection of research reports.

Vulvovaginal Candidiasis - Pipeline Review, H1 2016, provides an overview of the Vulvovaginal Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=713867

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis
- The report reviews pipeline therapeutics for Vulvovaginal Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vulvovaginal Candidiasis therapeutics and enlists all their major and minor projects
- The report assesses Vulvovaginal Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vulvovaginal Candidiasis

Browse Detail Report With TOC @ http://www.researchmoz.us/vulvovaginal-candidiasis-pipeline-review-h1-2016-report.html

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vulvovaginal Candidiasis Overview 6
Therapeutics Development 7
Pipeline Products for Vulvovaginal Candidiasis - Overview 7
Vulvovaginal Candidiasis - Therapeutics under Development by Companies 8
Vulvovaginal Candidiasis - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Unknown Stage Products 11
Vulvovaginal Candidiasis - Products under Development by Companies 12
Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development 13
Cidara Therapeutics, Inc. 13
Grupo Ferrer Internacional, S.A. 14
NovaDigm Therapeutics, Inc. 15
Scynexis, Inc. 16
TGV-Laboratories 17
Viamet Pharmaceuticals, Inc. 18
Vulvovaginal Candidiasis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=713867

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

This release was published on openPR.